Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

4.480 +0.090 (+2.05%)
Streaming Delayed Price Updated: 11:03 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 Next >
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)... 
Via Benzinga
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension ↗
Via Chartmill
News headline image
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Why Did PRLD Stock Surge 13% Today? ↗
Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 
Via Stocktwits
News headline image
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
Prelude Therapeutics beats Q3 2025 earnings estimates, extends cash runway into 2027, and advances its precision oncology pipeline. 
Via Chartmill
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Tuesday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.